ADP-A2M4CD8 as Monotherapy or in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

ADP-A2M4CD8 as Monotherapy or in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Conditions:   Endometrial Cancer;   Esophageal Cancer;   Esophagogastric Junction (EGJ);   Gastric (Stomach) Cancer;   Head and Neck Cancer;   Melanoma;   Ovarian Cancer;   Non-small Cell Lung (NSCLC);   Urothelial Cancer
Intervention:   Genetic: Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks
Sponsors:   Adaptimmune;   ICON plc
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 4, 2022Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments